Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.

Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, Huynh A, Deconinck E, Wu D, Bourhis JH, Cahn JY, Polge E, Mohty M, Savani BN, Nagler A.

Am J Hematol. 2018 Jul 7. doi: 10.1002/ajh.25211. [Epub ahead of print]

PMID:
29981272
2.

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Salvatore D, Labopin M, Ruggeri A, Battipaglia G, Ghavamzadeh A, Ciceri F, Blaise D, Arcese W, Socié G, Bourhis JH, Van Lint M, Bruno B, Huynh A, Santarone S, Deconinck E, Mohty M, Nagler A.

Haematologica. 2018 May 10. pii: haematol.2018.189258. doi: 10.3324/haematol.2018.189258. [Epub ahead of print]

3.

Development of a quantitative PCR detecting Cunninghamella bertholletiae to help in diagnosing this rare and aggressive mucormycosis.

Bellanger AP, Berceanu A, Rocchi S, Valot B, Fontan J, Chauchet A, Belin N, Scherer E, Deconinck E, Navellou JC, Millon L.

Bone Marrow Transplant. 2018 Apr 30. doi: 10.1038/s41409-018-0194-5. [Epub ahead of print]

PMID:
29712993
4.

Factors related to the outcome of prophylactic platelet transfusions in patients with hematologic malignancies: an observational study.

Seigeot A, Desmarets M, Rumpler A, Leroux F, Deconinck E, Monnet E, Bardiaux L.

Transfusion. 2018 Jun;58(6):1377-1387. doi: 10.1111/trf.14592. Epub 2018 Mar 14.

PMID:
29542122
5.

Incidence, Risk Factors and Long-Term Outcome of Acute Leukemia Patients with Early Candidemia after Allogeneic Stem Cell Transplantation. A Study by the Acute Leukemia and Infectious Diseases Working Parties of EBMT.

Cesaro S, Tridello G, Blijlevens N, Ljungman P, Craddock C, Michallet M, Martin A, Snowden JA, Mohty M, Maertens J, Passweg J, Petersen E, Nihtinen A, Isaksson C, Milpied N, Rohlich PS, Deconinck E, Crawley C, Ledoux MP, Hoek J, Nagler A, Styczynski J.

Clin Infect Dis. 2018 Feb 22. doi: 10.1093/cid/ciy150. [Epub ahead of print]

PMID:
29481599
6.

Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Tozatto-Maio K, Giannotti F, Labopin M, Ruggeri A, Volt F, Paviglianiti A, Kenzey C, Hayashi H, Cornelissen J, Michallet M, Karakasis D, Deconinck E, Rohrlich PS, de la Tour RP, Blaise D, Petersen E, D'Aveni M, Sengeloev H, Lamy T, Russell NH, Forcade E, Craddock CF, Nagler A, Gluckman E, Rocha V.

Biol Blood Marrow Transplant. 2018 Mar 1. pii: S1083-8791(18)30092-2. doi: 10.1016/j.bbmt.2018.02.014. [Epub ahead of print]

PMID:
29477777
7.

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.

Saraceni F, Labopin M, Hamladji RM, Mufti G, Socié G, Shimoni A, Delage J, Deconinck E, Chevallier P, Blaise D, Sanz J, Huynh A, Forcade E, Savani BN, Mohty M, Nagler A; Acute Leukemia Working Party of the European society for Blood and Marrow Transplantation (EBMT).

Oncotarget. 2017 Dec 15;9(3):3379-3393. doi: 10.18632/oncotarget.23273. eCollection 2018 Jan 9.

8.

Detection and identification of multiple adulterants in plant food supplements using attenuated total reflectance-Infrared spectroscopy.

Deconinck E, Aouadi C, Bothy JL, Courselle P.

J Pharm Biomed Anal. 2018 Apr 15;152:111-119. doi: 10.1016/j.jpba.2018.01.047. Epub 2018 Feb 3.

PMID:
29414001
9.

Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.

Garban F, Guyard A, Labussière H, Bulabois CE, Marchand T, Mounier C, Caillot D, Bay JO, Coiteux V, Schmidt-Tanguy A, Le Niger C, Robin C, Ladaique P, Lapusan S, Deconinck E, Rolland C, Foote AM, François A, Jacquot C, Tardivel R, Tiberghien P, Bosson JL; Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group.

JAMA Oncol. 2018 Apr 1;4(4):468-475. doi: 10.1001/jamaoncol.2017.5123.

PMID:
29392283
10.

Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia.

Peffault de Latour R, Tabrizi R, Marcais A, Leblanc T, Lamy T, Mohty M, Tavitian S, Jubert C, Pasquet M, Galambrun C, Nguyen S, Cahn JY, Braun T, Deconinck E, Bay JO, Sicre de Fontbrune F, Barraco F, Socié G.

Am J Hematol. 2018 May;93(5):635-642. doi: 10.1002/ajh.25050. Epub 2018 Feb 14.

PMID:
29377260
11.

A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XNTM analyzers in routine laboratory practice.

Schillinger F, Sourdeau E, Boubaya M, Baseggio L, Clauser S, Cornet E, Debord C, Defour JP, Dubois F, Eveillard M, Galoisy AC, Geay MO, Mullier F, Nivaggioni V, Soenen V, Morel P, Garnache-Ottou F, Ronez E, Bardet V, Deconinck E.

Scand J Clin Lab Invest. 2018 May;78(3):159-164. doi: 10.1080/00365513.2018.1423702. Epub 2018 Jan 8.

PMID:
29310473
12.

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1.

Versluis J, Labopin M, Ruggeri A, Socie G, Wu D, Volin L, Blaise D, Milpied N, Craddock C, Yakoub-Agha I, Maertens J, Ljungman P, Huynh A, Michallet M, Deconinck E, Chevallier P, Passweg J, Ciceri F, Mohty M, Cornelissen JJ, Nagler A.

Blood Adv. 2017 Feb 28;1(7):477-485. doi: 10.1182/bloodadvances.2016002386. eCollection 2017 Feb 28.

13.

Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.

Shimoni A, Labopin M, Savani B, Hamladji RM, Beelen D, Mufti G, Socié G, Delage J, Blaise D, Chevallier P, Forcade E, Deconinck E, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2018 Apr;24(4):751-757. doi: 10.1016/j.bbmt.2017.12.776. Epub 2017 Dec 13.

PMID:
29247780
14.

Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Decroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, Beckerich F, Suarez F, Chevallier P, Nguyen-Quoc S, Ledoux MP, Clement L, Hicheri Y, Guillerm G, Cornillon J, Contentin N, Carre M, Maillard N, Mercier M, Mohty M, Beguin Y, Bourhis JH, Charbonnier A, Dauriac C, Bay JO, Blaise D, Deconinck E, Jubert C, Raus N, Peffault de Latour R, Dhedin N.

Am J Hematol. 2018 Mar;93(3):416-423. doi: 10.1002/ajh.25004. Epub 2018 Jan 8.

PMID:
29226497
15.

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK.

J Intern Med. 2018 Apr;283(4):371-379. doi: 10.1111/joim.12720. Epub 2018 Jan 5.

PMID:
29214689
16.

More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.

Tiberghien P, Deconinck E, Adotevi O.

N Engl J Med. 2017 Nov 23;377(21):2101-2. doi: 10.1056/NEJMc1712460. No abstract available.

PMID:
29182255
17.

Identification of coffee leaves using FT-NIR spectroscopy and SIMCA.

Mees C, Souard F, Delporte C, Deconinck E, Stoffelen P, Stévigny C, Kauffmann JM, De Braekeleer K.

Talanta. 2018 Jan 15;177:4-11. doi: 10.1016/j.talanta.2017.09.056. Epub 2017 Sep 23.

PMID:
29108581
18.

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V; LYSA Group.

Blood. 2018 Jan 11;131(2):174-181. doi: 10.1182/blood-2017-07-793984. Epub 2017 Oct 23.

19.

Are injectable illegal polypeptide drugs safe? Case report demonstrating the presence of haemolytic Bacillus cereus in 2 illegal peptide drugs.

Janvier S, Wattijn E, Botteldoorn N, De Spiegeleer B, Deconinck E, Vanhee C.

Drug Test Anal. 2018 Apr;10(4):791-795. doi: 10.1002/dta.2304. Epub 2017 Dec 1. No abstract available.

PMID:
28941153
20.

Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault de Latour R, Marçais A, Bulabois CE, Bay JO, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-Agha I, Cornillon J, Mercier M, Turlure P, Charbonnier A, Rorhlich PS, N'Guyen S, Maillard N, Marchand T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Ann Oncol. 2017 Sep 1;28(9):2191-2198. doi: 10.1093/annonc/mdx274.

PMID:
28911060
21.

Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.

Philippe L, Ceroi A, Bôle-Richard E, Jenvrin A, Biichle S, Perrin S, Limat S, Bonnefoy F, Deconinck E, Saas P, Garnache-Ottou F, Angelot-Delettre F.

Haematologica. 2017 Nov;102(11):1861-1868. doi: 10.3324/haematol.2017.169326. Epub 2017 Aug 10.

22.

Analysis of illegal peptide drugs via HILIC-DAD-MS.

Janvier S, De Sutter E, Wynendaele E, De Spiegeleer B, Vanhee C, Deconinck E.

Talanta. 2017 Nov 1;174:562-571. doi: 10.1016/j.talanta.2017.06.034. Epub 2017 Jun 13.

PMID:
28738623
23.

Chemometrics and chromatographic fingerprints to classify plant food supplements according to the content of regulated plants.

Deconinck E, Sokeng Djiogo CA, Courselle P.

J Pharm Biomed Anal. 2017 Sep 5;143:48-55. doi: 10.1016/j.jpba.2017.05.032. Epub 2017 May 20.

PMID:
28554127
24.

Development and validation of a HS/GC-MS method for the simultaneous analysis of diacetyl and acetylpropionyl in electronic cigarette refills.

Barhdadi S, Canfyn M, Courselle P, Rogiers V, Vanhaecke T, Deconinck E.

J Pharm Biomed Anal. 2017 Aug 5;142:218-224. doi: 10.1016/j.jpba.2017.04.050. Epub 2017 May 4.

PMID:
28521275
25.

Detection of regulated herbs and plants in plant food supplements and traditional medicines using infrared spectroscopy.

Deconinck E, Djiogo CAS, Bothy JL, Courselle P.

J Pharm Biomed Anal. 2017 Aug 5;142:210-217. doi: 10.1016/j.jpba.2017.04.051. Epub 2017 May 8.

PMID:
28521274
26.

The use of Stationary Phase Optimized Selectivity Liquid Chromatography for the development of herbal fingerprints to detect targeted plants in plant food supplements.

Deconinck E, Djiogo CAS, Kamugisha A, Courselle P.

Talanta. 2017 Aug 1;170:441-450. doi: 10.1016/j.talanta.2017.04.028. Epub 2017 Apr 19.

PMID:
28501194
27.

Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.

Canaani J, Labopin M, Socié G, Nihtinen A, Huynh A, Cornelissen J, Deconinck E, Gedde-Dahl T, Forcade E, Chevallier P, Bourhis JH, Blaise D, Mohty M, Nagler A.

Am J Hematol. 2017 Jul;92(7):653-659. doi: 10.1002/ajh.24737. Epub 2017 May 26.

28.

Paecilomyces variotii Fungemia in a Patient with Lymphoma Needing Liver Transplant.

Bellanger AP, Cervoni JP, Faucher JF, Weil-Verhoeven D, Ginet M, Deconinck E, Grenouillet F.

Mycopathologia. 2017 Aug;182(7-8):761-765. doi: 10.1007/s11046-017-0131-y. Epub 2017 Apr 1.

PMID:
28365835
29.

Chromatographic fingerprinting as a strategy to identify regulated plants in illegal herbal supplements.

Custers D, Van Praag N, Courselle P, Apers S, Deconinck E.

Talanta. 2017 Mar 1;164:490-502. doi: 10.1016/j.talanta.2016.12.008. Epub 2016 Dec 6.

PMID:
28107963
30.

DNA damage response defect in Williams-Beuren syndrome.

Guenat D, Merla G, Deconinck E, Borg C, Rohrlich PS.

Int J Mol Med. 2017 Mar;39(3):622-628. doi: 10.3892/ijmm.2017.2861. Epub 2017 Jan 17.

31.

Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.

Wang L, Raffoux E, Thomas X, Yakoub-Agha I, Bouhris JH, de Botton S, Michallet M, Quoc SN, Chantepie S, Deconinck E, Caillot D, Turlure P, Vigouroux S, Pigneux A, Huynh A, Malfuson JV, Loschi M, Socie G, Dombret H, de la Tour RP, Cluzeau T.

Leuk Res. 2017 Mar;54:12-16. doi: 10.1016/j.leukres.2017.01.002. Epub 2017 Jan 5.

PMID:
28088653
32.

Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT.

Canaani J, Beohou E, Labopin M, Socié G, Huynh A, Volin L, Cornelissen J, Milpied N, Gedde-Dahl T, Deconinck E, Fegueux N, Blaise D, Mohty M, Nagler A.

Am J Hematol. 2017 Apr;92(4):344-350. doi: 10.1002/ajh.24640. Epub 2017 Feb 7.

33.

In vitro Dermal Absorption of Hydroquinone: Protocol Validation and Applicability on Illegal Skin-Whitening Cosmetics.

Desmedt B, Ates G, Courselle P, De Beer JO, Rogiers V, Hendrickx B, Deconinck E, De Paepe K.

Skin Pharmacol Physiol. 2016;29(6):300-308. doi: 10.1159/000454719. Epub 2017 Jan 5.

34.

A simple dilute and shoot methodology for the identification and quantification of illegal insulin.

Vanhee C, Janvier S, Moens G, Deconinck E, Courselle P.

J Pharm Anal. 2016 Oct;6(5):326-334. doi: 10.1016/j.jpha.2016.04.006. Epub 2016 Apr 22.

35.

Identification of epidermal growth factor (EGF), in an unknown pharmaceutical preparation suspected to contain insulin like growth factor 1 (IGF-1).

Vanhee C, Janvier S, Moens G, Goscinny S, Courselle P, Deconinck E.

Drug Test Anal. 2017 May;9(5):831-837. doi: 10.1002/dta.2029. Epub 2016 Jul 8. No abstract available.

PMID:
27390261
36.

Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT.

Paviglianiti A, Xavier E, Ruggeri A, Ceballos P, Deconinck E, Cornelissen JJ, Nguyen-Quoc S, Maillard N, Sanz G, Rohrlich PS, Garderet L, Volt F, Rocha V, Kroeger N, Gluckman E, Fegueux N, Mohty M.

Haematologica. 2016 Sep;101(9):1120-7. doi: 10.3324/haematol.2015.138917. Epub 2016 May 26.

37.

Chemometrics and the identification of counterfeit medicines-A review.

Krakowska B, Custers D, Deconinck E, Daszykowski M.

J Pharm Biomed Anal. 2016 Aug 5;127:112-22. doi: 10.1016/j.jpba.2016.04.016. Epub 2016 Apr 16. Review.

PMID:
27133184
38.

Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts.

Bôle-Richard E, Gamonet C, Certoux JM, Idirene I, Larosa F, Deconinck E, Mosseley AM, Tiberghien P, Borg C, Ferrand C, Deschamps M.

Gene Ther. 2016 Aug;23(8-9):664-72. doi: 10.1038/gt.2016.39. Epub 2016 May 12.

PMID:
27111151
39.

Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.

Philippe L, Helias P, Puyraveau M, Boulahdour H, Deconinck E, Daguindau E.

Bone Marrow Transplant. 2016 Aug;51(8):1140-2. doi: 10.1038/bmt.2016.67. Epub 2016 Apr 4. No abstract available.

PMID:
27042844
40.

Clustering and diagnostic modelling of slimming aids based on chromatographic and mass spectrometric fingerprints.

Custers D, Van Hoeck E, Courselle P, Apers S, Deconinck E.

Drug Test Anal. 2017 Feb;9(2):230-242. doi: 10.1002/dta.1964. Epub 2016 Mar 22.

PMID:
27006262
41.

Overview of skin whitening agents with an insight into the illegal cosmetic market in Europe.

Desmedt B, Courselle P, De Beer JO, Rogiers V, Grosber M, Deconinck E, De Paepe K.

J Eur Acad Dermatol Venereol. 2016 Jun;30(6):943-50. doi: 10.1111/jdv.13595. Epub 2016 Mar 8. Review.

PMID:
26953335
42.

Discriminating nicotine and non-nicotine containing e-liquids using infrared spectroscopy.

Deconinck E, Bothy JL, Barhdadi S, Courselle P.

J Pharm Biomed Anal. 2016 Feb 20;120:333-41. doi: 10.1016/j.jpba.2015.12.054. Epub 2015 Dec 30.

PMID:
26771132
43.

Testing of complementarity of PDA and MS detectors using chromatographic fingerprinting of genuine and counterfeit samples containing sildenafil citrate.

Custers D, Krakowska B, De Beer JO, Courselle P, Daszykowski M, Apers S, Deconinck E.

Anal Bioanal Chem. 2016 Feb;408(6):1643-56. doi: 10.1007/s00216-015-9275-0. Epub 2016 Jan 11.

PMID:
26753972
44.
45.

Chromatographic impurity fingerprinting of genuine and counterfeit Cialis® as a means to compare the discriminating ability of PDA and MS detection.

Custers D, Krakowska B, De Beer JO, Courselle P, Daszykowski M, Apers S, Deconinck E.

Talanta. 2016;146:540-8. doi: 10.1016/j.talanta.2015.09.029. Epub 2015 Sep 14.

PMID:
26695302
46.
47.
48.

Is shared decision-making vanishing at the end-of-life? A descriptive and qualitative study of advanced cancer patients' involvement in specific therapies decision-making.

Beaussant Y, Mathieu-Nicot F, Pazart L, Tournigand C, Daneault S, Cretin E, Godard-Marceau A, Chassagne A, Trimaille H, Bouleuc C, Cuynet P, Deconinck E, Aubry R.

BMC Palliat Care. 2015 Nov 16;14:61. doi: 10.1186/s12904-015-0057-4.

49.

Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy.

Chantepie SP, Michallet M, Blaise D, Maury S, Deconinck E, Tabrizi R, Contentin N, Mohty M, Nguyen S, Lioure B, Raus N, Peffault de Latour R, Yakoub-Agha I, Reman O; SFGM-TC group.

Bone Marrow Transplant. 2015 Dec;50(12):1586-8. doi: 10.1038/bmt.2015.206. Epub 2015 Sep 14. No abstract available.

PMID:
26367219
50.

Combining Aspergillus mitochondrial and ribosomal QPCR, in addition to galactomannan assay, for early diagnosis of invasive aspergillosis in hematology patients.

Bellanger AP, Millon L, Berceanu A, Grenouillet F, Grenouillet FE, Larosa F, Deconinck E.

Med Mycol. 2015 Sep;53(7):760-4. doi: 10.1093/mmy/myv051. Epub 2015 Jul 10.

PMID:
26162471

Supplemental Content

Loading ...
Support Center